Uploaded May 2025 | Updated November 2026, 3 hours ago
Dr. Petros Giannikopoulos, the Director of the Innovative Genomics Institute Clinical Laboratory at UC Berkeley, explains how a team of researchers and doctors created the first on-demand CRISPR therapy for a boy born with a deadly genetic disease and delivered it to him a mere six and a half months after birth.
The CRISPR treatment was administered safely, and the infant is now growing well and thriving, his doctors say. They hope that the treatment will make a liver transplant, which is usually required for survival, unnecessary.
The boy inherited two mutated genes that prevented him from breaking down the proteins in his food, which leads to a build-up of ammonia that destroys the liver and can cause lifelong neurologic damage.
Researchers at the University of California, Berkeley's Innovative Genome Institute (IGI) worked with the boy's physicians at the Children's Hospital of Philadelphia (CHOP) to test the safety and efficacy of a CRISPR base-editing therapy hospital doctors had developed. The tests helped fast-track approval of the new therapy by the U.S. Food and Drug Administration.
For full story, visit: news.berkeley.edu
Video by Sean Patrick Farrell
http://news.berkeley.edu/
facebook.com/UCBerkeley
twitter.com/UCBerkeley
instagram.com/ucberkeleyofficial
Dr. Petros Giannikopoulos, the Director of the Innovative Genomics Institute Clinical Laboratory at UC Berkeley, explains how a team of researchers and doctors created the first on-demand CRISPR therapy for a boy born with a deadly genetic disease and delivered it to him a mere six and a half months after birth.
The CRISPR treatment was administered safely, and the infant is now growing well and thriving, his doctors say. They hope that the treatment will make a liver transplant, which is usually required for survival, unnecessary.
The boy inherited two mutated genes that prevented him from breaking down the proteins in his food, which leads to a build-up of ammonia that destroys the liver and can cause lifelong neurologic damage.
Researchers at the University of California, Berkeley's Innovative Genome Institute (IGI) worked with the boy's physicians at the Children's Hospital of Philadelphia (CHOP) to test the safety and efficacy of a CRISPR base-editing therapy hospital doctors had developed. The tests helped fast-track approval of the new therapy by the U.S. Food and Drug Administration.
For full story, visit: news.berkeley.edu
Video by Sean Patrick Farrell
http://news.berkeley.edu/
facebook.com/UCBerkeley
twitter.com/UCBerkeley
instagram.com/ucberkeleyofficial










